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Abstract
The enantioselective total synthesis of spirofungins A (1) and B (2) is reported in 14 steps over the
longest linear sequence. Key steps include the use of thiazolidinethione mediated aldol reactions to
assemble the major fragments and installation of the C1–C6 side chain using a cross metathesis
reaction.
Spirofungins A (1) and B (2) were isolated in 1998 as secondary metabolites of Streptomyces
violaceusniger Tü 4113 as a 4:1 mixture.1 These spiroketal-containing natural products differ
only in the configuration about the C-15 spirocenter.2 The spirofungins, along with the
structurally related reveromycins,3 possess high antifungal activity against yeasts, including
the human pathogen Candida albicans. Further biological studies by the Kozmin group
revealed that spirofungin A suppresses the growth of several human cancer cell lines and
selectively inhibits isoleucyl-tRNA synthetase in vitro.4 The interesting structure and
biological profile of the spirofungins have resulted in two total syntheses4,5 as well as several
approaches to the spiroketal core.6 Additionally, the Shimizu group has begun investigating
derivatives of both spirofungin A and the reveromycins.7
Herein, we describe a highly convergent route to (−)-spirofungin A (1) and (+)-spirofungin B
(2) in which a cross metathesis reaction would be employed to install the C1–C6 side chain
3 in an efficient manner (Scheme 1). The cross metathesis partner, diene 4 or 5, was envisioned
to arise from the spiroketalization of ketone 6, available via a Horner-Wadsworth-Emmons
olefination, conjugate reduction sequence. The β-ketophosphonate 7, aldehyde 8, and ester 3
would be prepared using chiral auxiliary mediated aldol reactions developed in our
laboratories.8, 9
Initial efforts were focused on the synthesis of aldehyde 8. Due to the required anti substitution,
this fragment could not be accessed directly from a thiazolidinethione mediated propionate
aldol reaction (Scheme 2). Instead, aldehyde 8 was prepared via a diastereoselective acetate
aldol reaction followed by a Frater-Seebach alkylation.10 The acetate aldol reaction between
N-acetylthiazolidinethione 99 and 3-butenal11 gave rise to aldol adduct 10 in 81% yield and
>20:1 diastereomeric ratio. Direct displacement of the chiral auxiliary8 with iso-butyl alcohol
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provided ester 11 in 98% yield. The Frater-Seebach alkylation with methyl iodide proceeded
in high diastereoselectivity, however optimization was necessary to improve the rate of
conversion. After screening a variety of conditions it was determined that adding DMPU
resulted in the highest and most consistent yields.12 The alkylated ester 12 was obtained in
63% yield and a 10:1 diastereomeric ratio with the optimized conditions. Protection of 12 as
the triethylsilyl ether and reduction of the ester generated aldehyde 8 in five steps and 44%
overall yield.
The synthesis of β-ketophosphonate 7 commenced with an Evans syn propionate aldol
addition11 between N-propionylthiazolidinethione 13 and known aldehyde 1413 to deliver
secondary alcohol 15 in 88% yield and >20:1 diastereomeric ratio (Scheme 3). The resultant
alcohol was protected as the triethylsilyl ether and reductive removal of the thiazolidinethione
auxiliary gave rise to aldehyde 16 in 81% yield over the two steps.
A Wittig reaction with stabilized ylide 17 was employed to homologate the aldehyde to the
α,β-unsaturated ester. Upon 1,4-reduction with di-iso-butylaluminum hydride mediated by
MeCu,14 ester 18 was obtained in 83% yield. Treatment of ester 18 with lithiated dimethyl
methylphosphonate15 furnished β-ketophosphonate 7 in 87% yield and 48% overall yield for
the six steps.
With both β-ketophosphonate 7 and aldehyde 8 in hand, formation of the spiroketal precursor
via a modified Horner-Wadsworth-Emmons olefination16 was next explored. Treatment of 7
with barium hydroxide followed by addition of aldehyde 8 formed the desired C13–14 bond.
Conjugate reduction14 of the resultant enone generated ketone 6 in 94% yield. Exposure of the
ketone to PPTS in methanol resulted in facile cleavage of the silyl protecting groups and
spontaneous spiroketalization to provide a 2:1 mixture of spiroketals 19 (15S-isomer) and 20
(15R-isomer). NOESY and COSY NMR analysis determined that the major product
corresponded to the spiroketal core of spirofungin A. The spiroketals were readily separated
by flash column chromatography to give 19 and 20 in 56% and 26% yields respectively, each
of which was carried on separately for the remaining steps in the synthesis.
Introduction of the desired oxidation state of C24 was achieved via a manganese dioxide
oxidation employing sodium cyanide and methanol17 to deliver methyl esters 21 and 22 each
in 78% yield. To arrive at the desired cross metathesis partner, installation of the C6–C8 diene
was accomplished via a sequential cross metathesis/Wittig reaction.18 Treatment of 21 or 22
with methacrolein and Grubbs second generation catalyst gave rise to enals 23 and 24 in 74%
yield. A methylene Wittig19 olefination introduced the terminal olefin, providing dienes 4 and
5 in 86% and 75% yield respectively.
Having developed an efficient route to the spiroketal core, focus was shifted to synthesis and
appendage of the C1–C6 side chain. Allylic alcohol 3 could be generated in a sequence
analogous to that used to prepare β-ketophosphonate 7 (Scheme 4). Beginning with an Evans
syn propionate aldol reaction between N-propionylthiazolidinethione 13 and acrolein gave
aldol adduct 25 in 96% yield and excellent diastereoselectivity. The alcohol was then protected
as the triethylsilyl ether and the auxiliary reductively cleaved to deliver aldehyde 26 in 92%
yield over the two steps. A Wittig reaction with ylide 17 and removal of the silyl protecting
group furnished allylic alcohol 3 in excellent yield over the five steps.
The major bond forming event that remained was introduction of the C6–C7 bond via a cross
metathesis reaction of either diene with allylic alcohol 3. Based on the previous success of a
cross metathesis between a similarly substituted diene and allylic alcohol from our group,20
we anticipated the proposed cross metathesis between diene 4 or 5 and allylic alcohol 3 to be
selective for the desired E alkene.21 While the reaction was highly selective, initial attempts
were plagued by low yields and conversion. Several reaction conditions and model substrates
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were examined in order to optimize the key cross metathesis reaction. Ultimately, it was found
that to obtain the highest yields, it was necessary to add the ruthenium catalyst as a solution
over several hours. Under the optimized conditions, the cross metathesis products 27 and 28
were obtained in 83% and 71% yield respectively based on recovered diene. Finally, employing
conditions used by Shimizu,5 hydrolysis of the diester with lithium hydroxide provided (−)-
spirofungin A (1) in 87% yield and (+)-spirofungin B (2) in 88% yield.
In summary, a highly convergent total synthesis of spirofungins A and B has been completed
in 14 steps as the longest linear sequence from known aldehyde 14. The key fragments were
assembled using the thiazolidinethione mediated propionate and acetate aldol reactions
developed in our laboratories. A cross metathesis reaction provided an efficient strategy for
appending the right-hand side chain to the spiroketal core.
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Retrosynthetic analysis of the spirofungins.
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Synthesis of aldehyde 8.
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Synthesis of spiroketals 4 and 5.
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Synthesis of allylic alcohol 3.
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Total synthesis of spirofungins A and B.
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